Healthcare Sector Stock Rankings: Q2 2026

Methodology

Scores reflect a composite of growth quality, valuation, pipeline optionality, and macro defensive positioning. Sector-adjusted percentiles applied across eight large-cap names.

---

Ranked List

1. Eli Lilly (LLY) — $948.45 | Score: 73

Recommendation: Overweight

LLY tops the healthcare ranking with sector-leading conviction. GLP-1 franchise momentum remains the central thesis — tirzepatide's commercial execution continues to impress, with new indications and formulations expanding the addressable market. Pipeline optionality (orforglipron oral GLP-1, combination therapies) provides secular growth legs. Valuation is premium but supported by fundamentals trajectory.

Key Catalysts: tirzepatide label expansions, oral GLP-1 data readouts, pipeline partnership announcements

---

2. Merck & Co. (MRK) — $111.38 | Score: 65

Recommendation: Overweight

MRK earns a solid second place on the strength of its Keytruda franchise durability and oncology pipeline depth. While not a direct GLP-1 play, MRK's partnership ecosystem and internal pipeline give indirect exposure to the obesity treatment wave. Free cash flow generation supports capital returns and M&A optionality.

Key Catalysts: Keytruda indication expansions, latreporfin data, business development activity

---

3. UnitedHealth Group (UNH) — $379.98 | Score: 60

Recommendation: Overweight

UNH provides defensive healthcare exposure with a high-quality, diversified revenue base spanning insurance and Optum services. The stock has absorbed macro concerns and legal/regulatory noise; current positioning offers resilient earnings power at a reasonable multiple. Political risk on healthcare policy remains a overhang but is largely priced in.

Key Catalysts: Optum growth acceleration, medical cost trends, policy clarity

---

4. AbbVie (ABBV) — $201.55 | Score: 58

Recommendation: Market Perform

ABBV's Humira biosimilar headwinds are largely priced in, and the Skyrizi/Rinvoq immunology franchise provides growth offset. Newer acquisitions in aesthetics and neuroscience diversify the revenue mix. The challenge is visibility on sustained double-digit growth as the biosimilar impact fades. Current valuation adequately reflects near-term expectations.

Key Catalysts: Immunology franchise acceleration, aesthetics recovery, pipeline readouts

---

5. Johnson & Johnson (JNJ) — $221.32 | Score: 48

Recommendation: Market Perform

JNJ presents an interesting recovery play after a challenging 2024. Legal reserves normalization and strong pharma performance drove 90%+ net income growth in FY2025. However, the underlying franchise faces typical large-cap pharma headwinds: pricing pressure, generic erosion, and pipeline uncertainty. Medtech provides stability but not rerating catalyst.

Key Catalysts: Legal reserve changes, pharma pipeline milestones, medtech procedure volumes

---

6. Thermo Fisher Scientific (TMO) — $465.00 | Score: 53

Recommendation: Market Perform

TMO offers high-quality exposure to the life sciences tools and contract services space. The business model provides recession-resilient demand via essential lab consumables and services. However, growth has normalized post-pandemic and valuation remains elevated relative to historical averages. Better opportunities elsewhere in the sector.

Key Catalysts: M&A activity, emerging market expansion, academic funding trends

---

7. Abbott Laboratories (ABT) — $84.32 | Score: 53

Recommendation: Market Perform

ABT's diversified model spans diagnostics, medical devices, nutrition, and established pharma. FreeStyle Libre continues as a standout growth driver in diabetes care. The challenge is lapping difficult comparisons while maintaining organic growth momentum. Solid but unspectacular.

Key Catalysts: Libre growth trajectory, device pipeline approvals, nutrition recovery

---

8. Pfizer (PFE) — $25.68 | Score: 43

Recommendation: Underweight

PFE remains at the sector's bottom, reflecting significant challenges: post-COVID revenue normalization, pipeline setbacks, and a transformation program still in early innings. The valuation appears tempting on absolute terms, but the fundamental picture lacks near-term catalysts. Turnaround stories require patience most investors don't have.

Key Catalysts: Pipeline data readouts, business development, cost transformation progress

---

Sector Summary

---

Scores updated as of 2026-05-10 12:00 UTC. For informational purposes only. Not investment advice.